THURSDAY, Oct. 5, 2023 (HealthDay News) For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a
THURSDAY, Oct. 5, 2023 (HealthDay News) For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a
Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany, discussed the importance of good communication between health care providers and patients with chronic myeloid leukemia (CML).
In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.